Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash from Operations (2021 - 2025)

Kiniksa Pharmaceuticals International's Cash from Operations history spans 5 years, with the latest figure at 53894000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 187.13% year-over-year to 53894000.0; the TTM value through Dec 2025 reached 137985000.0, up 437.14%, while the annual FY2025 figure was 137985000.0, 437.14% up from the prior year.
  • Cash from Operations reached 53894000.0 in Q4 2025 per KNSA's latest filing, up from 33677000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 62053000.0 in Q3 2022 to a low of 40122000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 2824200.0, with a median of 875500.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: tumbled 113.16% in 2024, then surged 1606.13% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 18884000.0 in 2021, then skyrocketed by 38.7% to 11576000.0 in 2022, then skyrocketed by 137.36% to 4325000.0 in 2023, then surged by 333.99% to 18770000.0 in 2024, then skyrocketed by 187.13% to 53894000.0 in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Cash from Operations are 53894000.0 (Q4 2025), 33677000.0 (Q3 2025), and 28090000.0 (Q2 2025).